A Phase 1, Open Label, Dose Characteristic Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intravenous and Subcutaneous Doses of GSK2315698A in Patients With Systemic Amyloidosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update:
06 Sep 2023
Note:
-
Adis is an information provider.
-
Final gross price and currency may vary according to local VAT and billing address.
-
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
-
A link to download a PDF version of the trial profile will be included in your email receipt.